Should You Add Penumbra Stock to Your Portfolio Right Now?

Penumbra, Inc.’s (PEN) thrombectomy business is thriving, driven by growing sales of the U.S. vascular thrombectomy and CAVT (computer-assisted vacuum thrombectomy) line of products. The company anticipates strong early adoption of its computer-aided thrombectomy products in Europe, paving the way for wider international expansion. Sound financial health also bodes well for the stock. Meanwhile, adverse macroeconomic impacts and intense competition may pose operational risks for the company.               I ...